eli lilly tirzepatide fda approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Tirzepatide approved for obesity by

GLP-1s, appetite & nutrition GLP-1 receptor agonists work by slowing digestion and reducing appetite, which leads to lower overall food intake

J Biol Eng 12:15

Consider how obesity is associated with heart disease, stroke, Type 2 diabetes, some cancers, fatty liver disease, obstructive sleep apnea, and other life-altering and life-threatening conditions too numerous to list here

GLP-1 RA has been also reported to be useful not only to control diabetes, but also to reduce the risks of cardiovascular diseases, obesity and renal disorders [4]

What the evidence shows: Semaglutide 3-month weight loss results Clinical trials show that most individuals using semaglutide for weight management lose 6-7% of their body weight within the first three months